Vor Biopharma (VOR) Cash & Equivalents (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Cash & Equivalents data on file, last reported at $169.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 239.43% year-over-year to $169.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.9 million (up 239.43% YoY) and the FY2025 annual result came in at $396.5 million, up 383.82% from the prior year.
• Cash & Equivalents retreated to $169.9 million in Q1 2026 per VOR's latest filing, from $396.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $396.5 million in Q4 2025 and bottomed at $31.4 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $60.8 million (2022), against an average of $96.8 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 65.71%; it then surged 383.82% in 2025.
• Tracing VOR's Cash & Equivalents over 5 years: stood at $57.7 million in 2022, then tumbled by 45.66% to $31.4 million in 2023, then soared by 161.32% to $81.9 million in 2024, then surged by 383.82% to $396.5 million in 2025, then slumped by 57.16% to $169.9 million in 2026.
• Per Business Quant, the three latest VOR Cash & Equivalents figures stand at $169.9 million (Q1 2026), $396.5 million (Q4 2025), and $160.5 million (Q3 2025).

Peer Comparison